Cargando…
Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies
Chimeric antigen receptor (CAR) T-cell therapy has yielded impressive outcomes and transformed treatment algorithms for hematological malignancies. To date, five CAR T-cell products have been approved by the US Food and Drug Administration (FDA). Nevertheless, some significant toxicities pose great...
Autores principales: | Xiao, Xinyi, Huang, Shengkang, Chen, Sifei, Wang, Yazhuo, Sun, Qihang, Xu, Xinjie, Li, Yuhua |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8600921/ https://www.ncbi.nlm.nih.gov/pubmed/34794490 http://dx.doi.org/10.1186/s13046-021-02148-6 |
Ejemplares similares
-
Challenges and Clinical Strategies of CAR T-Cell Therapy for Acute Lymphoblastic Leukemia: Overview and Developments
por: Xu, Xinjie, et al.
Publicado: (2021) -
Deciphering and advancing CAR T-cell therapy with single-cell sequencing technologies
por: Huang, Shengkang, et al.
Publicado: (2023) -
Consolidative Hematopoietic Stem Cell Transplantation After CD19 CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: A Systematic Review and Meta-analysis
por: Xu, Xinjie, et al.
Publicado: (2021) -
Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapy
por: Wang, Zhenguang, et al.
Publicado: (2018) -
Interleukin Inhibitors in Cytokine Release Syndrome and Neurotoxicity Secondary to CAR-T Therapy
por: Ferreros, Puri, et al.
Publicado: (2022)